Investigation of the Anti-inflammatory Effect of Ketamine in Cardiac Surgery
Investigation of the Anti-inflammatory Effect of Ketamine in Cardiac Surgery : Randomızed Controlled Trıal
Background:
Cardiac surgery with cardiopulmonary bypass induces a systemic inflammatory response that may contribute to postoperative complications. Ketamine has been investigated for its potential immunomodulatory effects. This randomised controlled trial evaluated the effects of intraoperative ketamine administration on postoperative inflammatory biomarkers and clinical outcomes in patients undergoing elective cardiac surgery.
Methods:
This single-centre, randomised, controlled, single-blind trial was conducted at Necmettin Erbakan University Meram Faculty of Medicine Hospital, Türkiye. Between 30 October 2022 and 30 March 2023, 177 patients were assessed for eligibility, of whom 166 provided written informed consent and were randomised to the ketamine (n = 83) or control (n = 83) group.
All patients received standard general anaesthesia. In addition, the ketamine group received an intravenous ketamine bolus of 1 mg/kg at induction, followed by a continuous intraoperative infusion of 2.4 mg/kg/h.
The two primary outcomes specified in the original study protocol dated 5 September 2022 were neutrophil-to-lymphocyte ratio (NLR) and C-reactive protein (CRP), measured on postoperative day 1. The prespecified secondary outcomes included postoperative pain intensity assessed using the Numeric Rating Scale (NRS) and Prince Henry Hospital Pain Score (PHHPS), time to extubation, intensive care unit length of stay, and hospital length of stay.
Additional inflammatory parameters, including platelet-to-lymphocyte ratio (PLR), systemic inflammatory response index (SIRI), systemic immune-inflammation index (SII), and derived measures of perioperative biomarker changes, were evaluated in post hoc exploratory analyses. Additional clinical outcomes, including 28-day all-cause mortality, were also assessed on an exploratory basis.
Six randomised patients (three per group) died before postoperative day 1 biomarker measurements could be obtained. Consequently, 160 patients (80 per group) were included in the primary biomarker analyses, while all 166 randomised patients were included in the 28-day mortality analysis.
The study was retrospectively registered at ClinicalTrials.gov on 30 March 2026, after completion of recruitment and data collection.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Participants and Study Design
This was a single-centre, randomised, controlled, single-blind clinical trial conducted at Necmettin Erbakan University Meram Faculty of Medicine Hospital, Türkiye. The study included adults aged 18-80 years who were scheduled to undergo elective cardiac surgery, were able to provide written informed consent, and could reliably communicate their symptoms to the research team.
Exclusion criteria included contraindications to anaesthesia; cognitive impairment or communication difficulties; end-stage renal disease requiring haemodialysis; pregnancy or breastfeeding; known allergy to ketamine; left ventricular ejection fraction below 35%; emergency or repeat cardiac surgery; significant cardiac arrhythmia; morbid obesity; psychiatric disorders; hepatic insufficiency; use of anti-inflammatory medications; preoperative white blood cell count ≥15 × 10³/µL; C-reactive protein (CRP) ≥30 mg/L; and refusal to participate.
Between 30 October 2022 and 30 March 2023, 177 patients were assessed for eligibility. Eleven individuals were excluded before providing written research consent and before randomisation. Consequently, 166 patients provided written informed consent and were randomised to the ketamine group (n = 83) or the control group (n = 83).
Six randomised patients (three in each group) died intraoperatively or within the first 24 postoperative hours, before postoperative day 1 inflammatory biomarker measurements could be obtained. Therefore, the primary biomarker analyses included 160 patients (80 per group). All 166 randomised patients were included in the 28-day all-cause mortality analysis.
The original study protocol (Version 1.0, dated 5 September 2022) received ethics committee approval on 14 September 2022 (decision no. 2022/926). Authorisation to initiate the clinical trial was granted by the Turkish Medicines and Medical Devices Agency on 26 October 2022 (application no. 22-AKD-189).
The study was retrospectively registered at ClinicalTrials.gov on 30 March 2026, after completion of recruitment and data collection.
Randomisation and Blinding
Patients were randomly allocated to the ketamine or control group using a sealed, opaque envelope method involving the drawing of lots, as specified in the original study protocol. Allocation was performed by an investigator who was not otherwise involved in the study.
Patients were blinded to their treatment allocation. The anaesthesia team administering the study intervention was not blinded.
Anaesthesia Protocol
Upon arrival in the operating room, all patients received intravenous premedication with midazolam (1 mg) and fentanyl (50 µg). Standard monitoring, including electrocardiography and peripheral oxygen saturation, was applied. Invasive arterial blood pressure monitoring was established by radial artery catheterisation using a 20-gauge cannula under local anaesthesia.
All weight-based drug doses were calculated using adjusted body weight.
Anaesthesia was induced with intravenous midazolam (0.1 mg/kg), fentanyl (3 µg/kg), and rocuronium (0.6 mg/kg) in both groups.
In addition to the standard induction regimen, patients allocated to the ketamine group received an intravenous ketamine bolus of 1 mg/kg at induction, followed by a continuous intravenous infusion of 2.4 mg/kg/h throughout the intraoperative period. Patients allocated to the control group received standard anaesthesia without additional ketamine administration.
Following adequate muscle relaxation and induction of anaesthesia, endotracheal intubation was performed. A central venous catheter was subsequently inserted through the right internal jugular vein.
Intraoperative analgesic and haemodynamic management was guided by haemodynamic parameters and Surgical Pleth Index (SPI) monitoring. Baseline heart rate, systolic arterial pressure, diastolic arterial pressure, and mean arterial pressure were recorded before induction after premedication. Additional haemodynamic measurements were obtained immediately before intubation, every minute during the first five minutes after intubation, and subsequently at 10-minute intervals throughout surgery.
Anaesthesia was maintained using intravenous remifentanil (0.1-0.3 µg/kg/min) and inhaled sevoflurane (0.5-1 minimum alveolar concentration). An SPI target range of 40-60 was used together with haemodynamic variables to guide intraoperative management. Changes of approximately 20-30% from baseline haemodynamic values were considered clinically relevant.
Hypotension was managed using ephedrine or norepinephrine, as clinically indicated. Hypertension was managed by adjusting the administration of remifentanil and sevoflurane.
Approximately one hour before the end of surgery, all patients received intravenous morphine (0.1 mg/kg) for postoperative analgesia. Intravenous paracetamol (10-15 mg/kg) was administered every eight hours during the postoperative period.
Following surgery, patients were transferred to the intensive care unit (ICU) under mechanical ventilation. Postoperative sedoanalgesia was maintained using remifentanil (0.05-0.1 µg/kg/min) and dexmedetomidine (0.5-1 µg/kg/h) infusions until extubation criteria were met.
Patients were assessed for weaning from mechanical ventilation according to clinical status, blood gas findings, haemodynamic stability, and normothermia. Extubation was performed when the relevant clinical criteria had been fulfilled.
Post-extubation rescue analgesia consisted of intravenous tramadol (1 mg/kg, generally 50-100 mg), administered when required.
Outcome Measures
The original ethics-approved study protocol, dated 5 September 2022, specified two primary outcomes and five secondary outcome measures.
Prespecified primary outcomes
- Neutrophil-to-lymphocyte ratio (NLR), measured on the morning of postoperative day 1.
- C-reactive protein (CRP) concentration, measured on the morning of postoperative day 1.
NLR was calculated by dividing the absolute neutrophil count by the absolute lymphocyte count. CRP was measured in mg/L using routine laboratory testing.
Prespecified secondary outcomes
- Postoperative pain intensity assessed using the Numeric Rating Scale (NRS).
- Postoperative pain intensity assessed using the Prince Henry Hospital Pain Score (PHHPS).
- Time to tracheal extubation.
- Length of ICU stay.
- Length of hospital stay.
Postoperative pain was assessed using NRS and PHHPS during the early postoperative period. The NRS ranges from 0 (no pain) to 10 (worst imaginable pain). PHHPS is a categorical pain assessment scale ranging from 0 to 4.
Extubation time was recorded in hours, ICU length of stay in hours, and hospital length of stay in days.
Post hoc exploratory outcomes and analyses
Additional inflammatory indices, derived biomarker measures, and selected clinical outcomes were evaluated in analyses introduced after the original study protocol had been established.
Routine preoperative and postoperative day 1 laboratory measurements were used to assess white blood cell, neutrophil, lymphocyte, and platelet counts, together with derived inflammatory indices including platelet-to-lymphocyte ratio (PLR), systemic inflammatory response index (SIRI), and systemic immune-inflammation index (SII).
The derived indices were calculated as follows:
- NLR = neutrophil count / lymphocyte count
- PLR = platelet count / lymphocyte count
- SIRI = neutrophil count × monocyte count / lymphocyte count
- SII = platelet count × neutrophil count / lymphocyte count
Perioperative changes in inflammatory markers were calculated as postoperative minus preoperative values (delta values). Biomarker indices were calculated as postoperative-to-preoperative ratios.
Additional exploratory clinical assessments included intraoperative haemodynamic variables, vasoactive and inotropic support, additional postoperative analgesic requirements, and 28-day all-cause mortality.
Intraoperative vasoactive and inotropic support was quantified using the vasoactive-inotropic score (VIS), calculated as:
VIS = dopamine dose + dobutamine dose + 100 × epinephrine dose + 100 × norepinephrine dose + 10 × milrinone dose + 10,000 × vasopressin dose.
Catecholamine and milrinone doses were expressed in µg/kg/min, and vasopressin in U/kg/min. VIS during cardiopulmonary bypass and at the end of surgery was recorded.
The additional exploratory outcomes and derived analyses were not prespecified as primary outcomes in the original ethics-approved protocol and should be interpreted as hypothesis-generating.
Sample Size Calculation
The original sample size calculation was performed using G*Power before patient recruitment. The documented calculation, dated 15 June 2022, assumed a standardised effect size (Cohen's d) of 0.5537, a one-sided significance level of 0.05, and 95% statistical power, yielding a minimum required sample size of 144 participants (72 per group).
The original study protocol (Version 1.0, dated 5 September 2022) specified a target sample size of 160 participants (80 per group). Ultimately, 166 participants were randomised.
No formal pilot study was conducted to determine the sample size. The source used to derive the assumed effect size of 0.5537 and the specific primary outcome underlying the original calculation could not be verified retrospectively. The previously entered registry statement indicating that the calculation was based on a pilot study of 10 participants per group was incorrect and has been corrected retrospectively.
No adjustment for multiple testing of the two co-primary outcomes was incorporated into the documented sample size calculation.
Statistical Analysis
The original statistical analyses were performed using IBM SPSS Statistics (version 23.0; IBM Corp., Armonk, NY, USA). Additional post hoc analyses and statistical verification were conducted using Python with the SciPy and statsmodels packages.
Continuous variable distributions were assessed using the Shapiro-Wilk test. Normally distributed variables were presented as mean ± standard deviation, whereas non-normally distributed variables were reported as median (interquartile range). Categorical variables were presented as counts and percentages.
Between-group comparisons were performed using independent-samples t-tests for normally distributed continuous variables and Mann-Whitney U tests for non-normally distributed variables. Categorical variables were compared using Pearson's chi-square test or Fisher's exact test, as appropriate.
The reported hypothesis tests were two-sided, with p < 0.05 considered statistically significant in the original analyses. Although the original sample size calculation used a one-sided significance level, the reported outcome analyses were conducted using two-sided tests.
The original protocol specified postoperative day 1 NLR and CRP as the two primary outcomes without a prespecified adjustment for multiple testing. A Bonferroni-adjusted threshold of p < 0.025 was subsequently considered as a post hoc sensitivity analysis.
Additional post hoc analyses of covariance (ANCOVA) were conducted separately for postoperative NLR and CRP, using treatment group as the independent variable and the corresponding preoperative biomarker value as a covariate. Adjusted between-group differences and 95% confidence intervals were estimated using heteroskedasticity-robust (HC3) standard errors.
Further sensitivity analyses were performed using natural logarithm-transformed postoperative biomarker values, adjusted for the corresponding natural logarithm-transformed preoperative values. Treatment coefficients from these models were exponentiated and expressed as adjusted ketamine-to-control ratios with 95% confidence intervals.
Additional inflammatory indices, derived measures, and clinical outcomes introduced after data collection were analysed on an exploratory basis. Their findings were interpreted as hypothesis-generating rather than confirmatory.
The analyses of postoperative day 1 NLR and CRP were restricted to 160 patients with available measurements (80 per group). Six randomised patients died before these measurements could be obtained. Because these missing biomarker outcomes arose from death, they could not be assumed to be missing at random.
All 166 randomised patients (83 per group) were included in the 28-day mortality analysis.
Retrospective Registry Clarification
This study was retrospectively registered on 30 March 2026, after completion of recruitment and data collection. The initial registry record included outcome measures and classifications that were not fully aligned with the original ethics-approved protocol dated 5 September 2022.
The primary and secondary outcome classifications have been clarified with reference to the original protocol. Additional inflammatory indices, derived measures, and exploratory clinical analyses were not prospectively registered as primary or secondary outcomes.
These clarifications describe the differences between the original protocol and the retrospectively entered registry information. They do not constitute prospectively registered amendments to the study design.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Konya
-
Meram, Konya, Turkey (Türkiye), 42000
- Necmettin Erbakan University Meram Faculty of Medicine Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
- Patients aged 18-80 years.
- Scheduled to undergo elective cardiac surgery.
- Able to provide informed consent.
- Able to reliably communicate symptoms to the research team. Exclusion Criteria
- Contraindications to anesthesia.
- Cognitive impairment or communication barriers.
- End-stage renal failure (receiving routine hemodialysis).
- Pregnancy or breastfeeding.
- Known allergy to ketamine.
- Ejection fraction (EF) <35%.
- Emergency or repeat surgery.
- Arrhythmia.
- Morbid obesity.
- Psychiatric disorders.
- Hepatic failure.
- Use of anti-inflammatory medications.
- Preoperative white blood cell count (leukocyte) ≥15 × 10³/µL.
- C-reactive protein (CRP) ≥30 mg/L.
- Declined to participate in the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
No Intervention: control group
Standard treatment was administered to all patients. |
|
|
Active Comparator: ketamine group
In addition to standard treatment, ketamine was administered at a dose of 1 mg/kg during induction and as a continuous infusion at 2.4 mg/kg/h |
In addition to standard treatment, ketamine was administered at a dose of 1 mg/kg during induction and as a continuous infusion at 2.4 mg/kg/h
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Postoperative Day 1 Neutrophil-to-Lymphocyte Ratio (NLR)
Time Frame: Postoperative day 1 (morning)
|
NLR was calculated as the absolute neutrophil count divided by the absolute lymphocyte count, using routine blood tests obtained on the morning of postoperative day 1. |
Postoperative day 1 (morning)
|
|
Postoperative Day 1 C-Reactive Protein (CRP)
Time Frame: Postoperative day 1 (morning)
|
Serum C-reactive protein (CRP) concentration was measured in mg/L using routine blood tests obtained on the morning of postoperative day 1. |
Postoperative day 1 (morning)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Length of ICU Stay
Time Frame: From ICU admission to ICU discharge (up to 28 days)
|
Duration of stay in the intensive care unit, measured in hours. |
From ICU admission to ICU discharge (up to 28 days)
|
|
Length of Hospital Stay
Time Frame: From the date of surgery to hospital discharge (up to 28 days)
|
Total duration of hospitalization following surgery, measured in days. |
From the date of surgery to hospital discharge (up to 28 days)
|
|
Postoperative Pain Score (NRS)
Time Frame: First 24 hours after extubation
|
Pain severity assessed using the Numeric Rating Scale ranging from 0 (no pain) to 10 (worst pain). |
First 24 hours after extubation
|
|
Postoperative Pain Score (PHHPS)
Time Frame: Within the first 24 hours after extubation
|
Postoperative pain intensity and patient comfort were assessed using the Prince Henry Hospital Pain Score (PHHPS), a categorical scale ranging from 0 to 4, where 0 indicates no pain on coughing, 1 indicates pain on coughing but not on deep breathing, 2 indicates pain on deep breathing but not at rest, 3 indicates mild pain at rest, and 4 indicates severe pain at rest. |
Within the first 24 hours after extubation
|
|
Time to Extubation
Time Frame: From the end of surgery to tracheal extubation (within 48 hours postoperatively)
|
Time from the end of surgery to successful tracheal extubation, measured in hours. |
From the end of surgery to tracheal extubation (within 48 hours postoperatively)
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Turgay Atay, Konya City Hospital
- Study Director: gamze sarkılar, Necmettin Erbakan University Meram Faculty of Medicine Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2022/926
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
De-identified individual participant data underlying the published study results, together with an accompanying data dictionary, may be made available to qualified researchers upon reasonable request, subject to applicable institutional and ethical approvals and execution of an appropriate data-use agreement.
IPD Sharing Time Frame
Starting March 2026 and available upon reasonable request
IPD Sharing Access Criteria
De-identified individual participant data will be available upon reasonable request from the corresponding author (turgayatay@gmail.com). Requests will be evaluated based on scientific merit and ethical considerations. Data will be shared after approval of a research proposal and signing of a data use agreement.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.